OTCMKTS:PEYE

Precision Optics Competitors

$1.62
-0.07 (-3.86 %)
(As of 04/12/2021 10:04 AM ET)
Add
Compare
Today's Range
$1.62
Now: $1.62
$1.62
50-Day Range
$1.45
MA: $1.63
$1.80
52-Week Range
$0.55
Now: $1.62
$1.95
Volume1,050 shs
Average Volume11,534 shs
Market Capitalization$21.49 million
P/E RatioN/A
Dividend YieldN/A
Beta0.68

Competitors

Precision Optics (OTCMKTS:PEYE) Vs. SLNO, ECOR, ELMD, HSDT, FCRE, and CHFS

Should you be buying PEYE stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Precision Optics, including Soleno Therapeutics (SLNO), electroCore (ECOR), Electromed (ELMD), Helius Medical Technologies (HSDT), Fc Global Realty (FCRE), and CHF Solutions (CHFS).

Precision Optics (OTCMKTS:PEYE) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares Precision Optics and Soleno Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision Optics$9.92 million2.17$-1,430,000.00N/AN/A
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.60

Precision Optics has higher revenue and earnings than Soleno Therapeutics.

Analyst Recommendations

This is a summary of current ratings and price targets for Precision Optics and Soleno Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precision Optics0000N/A
Soleno Therapeutics00303.00

Soleno Therapeutics has a consensus price target of $8.6667, suggesting a potential upside of 673.81%. Given Soleno Therapeutics' higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than Precision Optics.

Profitability

This table compares Precision Optics and Soleno Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precision Optics-13.17%-46.31%-22.21%
Soleno TherapeuticsN/A-88.69%-51.63%

Risk & Volatility

Precision Optics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

Insider and Institutional Ownership

55.4% of Soleno Therapeutics shares are owned by institutional investors. 24.7% of Precision Optics shares are owned by insiders. Comparatively, 74.9% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Soleno Therapeutics beats Precision Optics on 7 of the 11 factors compared between the two stocks.

Precision Optics (OTCMKTS:PEYE) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

Risk and Volatility

Precision Optics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, electroCore has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500.

Valuation and Earnings

This table compares Precision Optics and electroCore's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision Optics$9.92 million2.17$-1,430,000.00N/AN/A
electroCore$2.39 million37.12$-45,150,000.00($1.54)-1.19

Precision Optics has higher revenue and earnings than electroCore.

Institutional and Insider Ownership

5.5% of electroCore shares are held by institutional investors. 24.7% of Precision Optics shares are held by company insiders. Comparatively, 24.9% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Precision Optics and electroCore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precision Optics-13.17%-46.31%-22.21%
electroCore-792.01%-109.15%-79.64%

Analyst Ratings

This is a breakdown of current ratings and target prices for Precision Optics and electroCore, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precision Optics0000N/A
electroCore00503.00

electroCore has a consensus price target of $3.70, suggesting a potential upside of 102.19%. Given electroCore's higher possible upside, analysts clearly believe electroCore is more favorable than Precision Optics.

Summary

electroCore beats Precision Optics on 7 of the 12 factors compared between the two stocks.

Electromed (NYSEAMERICAN:ELMD) and Precision Optics (OTCMKTS:PEYE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Electromed and Precision Optics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Electromed00203.00
Precision Optics0000N/A

Electromed presently has a consensus target price of $18.00, suggesting a potential upside of 79.10%. Given Electromed's higher possible upside, equities research analysts clearly believe Electromed is more favorable than Precision Optics.

Valuation & Earnings

This table compares Electromed and Precision Optics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Electromed$32.47 million2.67$4.16 million$0.4721.38
Precision Optics$9.92 million2.17$-1,430,000.00N/AN/A

Electromed has higher revenue and earnings than Precision Optics.

Volatility and Risk

Electromed has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Precision Optics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Profitability

This table compares Electromed and Precision Optics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Electromed11.44%12.39%11.15%
Precision Optics-13.17%-46.31%-22.21%

Insider and Institutional Ownership

37.5% of Electromed shares are held by institutional investors. 19.6% of Electromed shares are held by insiders. Comparatively, 24.7% of Precision Optics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Electromed beats Precision Optics on 10 of the 12 factors compared between the two stocks.

Helius Medical Technologies (NASDAQ:HSDT) and Precision Optics (OTCMKTS:PEYE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Helius Medical Technologies and Precision Optics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helius Medical Technologies01202.67
Precision Optics0000N/A

Helius Medical Technologies currently has a consensus target price of $20.00, indicating a potential upside of 15.74%. Given Helius Medical Technologies' higher possible upside, equities research analysts plainly believe Helius Medical Technologies is more favorable than Precision Optics.

Profitability

This table compares Helius Medical Technologies and Precision Optics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helius Medical Technologies-2,716.85%-328.07%-201.87%
Precision Optics-13.17%-46.31%-22.21%

Earnings & Valuation

This table compares Helius Medical Technologies and Precision Optics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helius Medical Technologies$1.50 million26.62$-9,780,000.00($12.94)-1.34
Precision Optics$9.92 million2.17$-1,430,000.00N/AN/A

Precision Optics has higher revenue and earnings than Helius Medical Technologies.

Risk & Volatility

Helius Medical Technologies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Precision Optics has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Fc Global Realty (OTCMKTS:FCRE) and Precision Optics (OTCMKTS:PEYE) are both small-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Profitability

This table compares Fc Global Realty and Precision Optics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fc Global Realty-4,265.28%-24.94%-9.42%
Precision Optics-13.17%-46.31%-22.21%

Volatility and Risk

Fc Global Realty has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500. Comparatively, Precision Optics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Fc Global Realty and Precision Optics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fc Global Realty0000N/A
Precision Optics0000N/A

Valuation & Earnings

This table compares Fc Global Realty and Precision Optics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fc Global Realty$40,000.00971.79$-2,040,000.00N/AN/A
Precision Optics$9.92 million2.17$-1,430,000.00N/AN/A

Precision Optics has higher revenue and earnings than Fc Global Realty.

Summary

Fc Global Realty beats Precision Optics on 4 of the 7 factors compared between the two stocks.

Precision Optics (OTCMKTS:PEYE) and CHF Solutions (NASDAQ:CHFS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Profitability

This table compares Precision Optics and CHF Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precision Optics-13.17%-46.31%-22.21%
CHF Solutions-254.26%-173.61%-131.01%

Insider & Institutional Ownership

65.1% of CHF Solutions shares are owned by institutional investors. 24.7% of Precision Optics shares are owned by insiders. Comparatively, 0.6% of CHF Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Precision Optics and CHF Solutions' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision Optics$9.92 million2.17$-1,430,000.00N/AN/A
CHF Solutions$5.51 million5.86$-18,110,000.00($279.28)-0.02

Precision Optics has higher revenue and earnings than CHF Solutions.

Analyst Ratings

This is a summary of recent ratings and target prices for Precision Optics and CHF Solutions, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precision Optics0000N/A
CHF Solutions00103.00

CHF Solutions has a consensus target price of $20.00, indicating a potential upside of 273.83%. Given CHF Solutions' higher possible upside, analysts plainly believe CHF Solutions is more favorable than Precision Optics.

Volatility and Risk

Precision Optics has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, CHF Solutions has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.


Precision Optics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.12-8.0%$89.29 millionN/A-1.47
electroCore logo
ECOR
electroCore
1.4$1.83-7.1%$88.71 million$2.39 million-2.32
Electromed logo
ELMD
Electromed
1.8$10.05-0.0%$86.78 million$32.47 million23.93News Coverage
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.28-3.4%$39.93 million$1.50 million-0.99
Fc Global Realty logo
FCRE
Fc Global Realty
0.5$0.10-90.1%$38.87 million$40,000.000.00Gap Up
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.35-0.9%$32.30 million$5.51 million-0.11
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.12-4.2%$32.27 million$6.57 million-0.01
ReShape Lifesciences logo
RSLS
ReShape Lifesciences
0.6$4.50-7.8%$25.59 million$15.09 million0.00Gap Down
Vaso logo
VASO
Vaso
0.9$0.12-3.0%$21.30 million$75.75 million5.93News Coverage
Gap Up
STRR
Star Equity
0.1$3.24-1.9%$15.95 million$114.18 million-1.03
Micron Solutions logo
MICR
Micron Solutions
0.1$3.48-13.8%$11.70 million$17.50 million24.86
GTHP
Guided Therapeutics
0.3$0.81-6.8%$10.41 million$40,000.00-3.35High Trading Volume
Gap Down
NIMU
Non-Invasive Monitoring Systems
0.5$0.03-0.0%$2.69 millionN/A0.00
RSLSD
ReShape Lifesciences
0.5$5.37-2.2%$1.94 million$610,000.000.00High Trading Volume
MAGAA
Magna-Lab
0.7$1.02-0.0%$1.20 millionN/A5.67
Nexeon MedSystems logo
NXNN
Nexeon MedSystems
0.7$0.55-0.0%$1.12 millionN/A0.00
ARDMQ
Aradigm
0.0$0.05-0.0%$764,000.00N/A0.00
IMRIS logo
IMRSQ
IMRIS
0.5$0.01-0.0%$447,000.00N/A0.00
Echo Therapeutics logo
ECTE
Echo Therapeutics
0.5$0.03-0.0%$356,000.00N/A0.00
ULGX
Urologix
0.6$0.01-0.0%$192,000.00N/A0.00
SCIE
SpectraScience
0.5$0.00-0.0%$177,000.00N/A0.00
AKSY
Aksys
0.0$0.00-0.0%$0.00N/A0.00
Escalon Medical logo
ESMC
Escalon Medical
0.5$0.34-2.9%$0.00$9.40 million-5.67Gap Up
HRTT
Heart Tronics
0.0$0.15-0.0%$0.00N/A0.00
IVVI
Ivivi Technologies
0.0$0.00-0.0%$0.00N/A0.00High Trading Volume
NWCI
NewCardio
0.5$0.00-0.0%$0.00N/A0.00
PECN
Photoelectron
0.2$0.03-0.0%$0.00N/A0.00
Trimedyne logo
TMED
Trimedyne
0.4$4.25-0.2%$0.00$5.57 million0.00
XCRP
Xcorporeal
0.0$0.00-0.0%$0.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.